This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Apple Pays Proview $60M to Settle iPad Dispute: Hot Trends

NEW YORK ( TheStreet) -- Popular searches on the Internet include Apple (AAPL - Get Report) as the tech titan has shelled out $60 million in the dispute over the name of its iPad tablet.

Apple agreed to pay the settlement to Proview Technology, a maker of computer screens and LED lights in China, after mediation talks. Proview had argued that Apple did not trademark the iPad name in China, despite doing so in other countries. Apple said its international trademark on the iPad name gave the company rights to the name everywhere.

The case went to a higher court in Guangdong after Proview won in a lower court late last year. Proview was declared bankrupt during the case.






Sony (SNE - Get Report) is trending as it said it will purchase cloud-gaming company Gaikai in an all-shares deal for $380 million.

Sony plans to create a new cloud-based service based on Gaikai's platform. Gaikai's platform enables users to stream games on various devices.

The deal is subject to regulatory approval. The date by which it is expected to be completed is unknown.

Just a week ago, Gaikai CEO David Perry denied there was any deal between the two companies.






Bristol-Myers Squibb (BMY) is another popular search. The company announced it will buy diabetes drugmaker Amylin Pharmaceuticals (AMLN) for $5.3 billion, or $31 a share, in cash. Including debt, the deal is valued at about $7 billion.

The deal will expand Bristol-Myers' portfolio of diabetes treatments with Amylin's products like Byetta and Bydureon.

In a follow-up deal, Bristol-Myers also will receive $3.4 billion from AstraZeneca (AZN - Get Report) to develop Amylin's drugs. Bristol-Myers and AstraZeneca already collaborate on several diabetes drugs. The boards of Amylin, Bristol-Myers and AstraZeneca have approved the two deals.

Amylin rejected a previous $3.5 billion takeover bid from Bristol-Myers.






The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TheStreet.com TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.54 -0.63%
BMY $65.67 6.06%
AZN $67.79 -0.72%
SNE $27.89 0.22%
FB $80.90 1.63%

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs